Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.05
+7.4%
$4.99
$3.42
$7.20
$264.36M1.751.54 million shs2.18 million shs
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$6.42
+2.6%
$5.34
$3.56
$12.92
$353.28M0.41353,083 shs226,078 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.13
$1.20
$0.83
$5.39
$70M1.13717,491 shs139,621 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$6.00
+6.4%
$3.83
$1.87
$11.40
$492.58M-0.111.46 million shs1.14 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+3.75%+2.62%+15.20%+10.33%-18.26%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
+4.86%-5.44%+6.83%+35.50%-44.11%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
0.00%-5.04%-3.42%+10.78%-67.53%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+10.37%+44.62%+101.43%-33.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.3002 of 5 stars
0.01.00.00.02.20.80.6
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
1.6457 of 5 stars
3.61.00.00.00.01.70.0
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
1.7149 of 5 stars
3.43.00.00.00.00.80.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.6139 of 5 stars
3.31.00.04.11.13.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.25
Buy$30.00367.29% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00696.46% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63160.42% Upside

Current Analyst Ratings Breakdown

Latest PYXS, ACB, ATXS, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/14/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.00
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
4/29/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$47.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.15$0.66 per share7.69$7.78 per share0.65
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.97 per shareN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.33N/AN/A$2.03 per share0.56
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1178.3311.48N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$94.26M-$1.870.00N/AN/AN/A-47.18%-31.26%8/11/2025 (Estimated)
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.590.00N/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.090.00N/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)

Latest PYXS, ACB, ATXS, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.36N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.61N/AN/AN/AN/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
8/4/2025Q2 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29N/AN/AN/AN/AN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/13/2025Q1 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.48-$0.58-$0.10-$0.58N/AN/A
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
17.39
17.39
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.75
7.75
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
30.89
30.89

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
4.50%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.25 million56.24 millionOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.43 million53.89 millionOptionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million55.38 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million86.03 millionNot Optionable

Recent News About These Companies

3 Penny Stocks Wall Street Sees With 243% Upside

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.05 +0.35 (+7.45%)
Closing price 04:00 PM Eastern
Extended Trading
$5.06 +0.01 (+0.12%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$6.42 +0.16 (+2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$6.42 0.00 (-0.08%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.13 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 +0.01 (+0.88%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$6.00 +0.36 (+6.38%)
Closing price 04:00 PM Eastern
Extended Trading
$6.00 +0.00 (+0.08%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.